John Whitesides
Overview
Explore the profile of John Whitesides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brandt C, Klein P, Badalamenti V, Gasalla T, Whitesides J
Epilepsy Behav
. 2020 Jan;
103(Pt A):106864.
PMID: 31937513
Objective: The objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of...
2.
Brodie M, Fakhoury T, McDonough B, Colson A, Stockis A, Elmoufti S, et al.
Epilepsy Res
. 2018 Jun;
145:55-62.
PMID: 29908435
To assess the association, if any, between brivaracetam (BRV)-induced elevated carbamazepine-10,11-epoxide (CBZ-E) and toxicity and efficacy in patients with epilepsy. Data were pooled from three double-blind, placebo-controlled, Phase III studies...
3.
Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C, Whitesides J, et al.
Epilepsy Res
. 2018 Feb;
141:73-82.
PMID: 29486396
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) approved for monotherapy (in the USA) and adjunctive treatment of focal (partial-onset) seizures...
4.
Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti S, Whitesides J
Epilepsy Behav
. 2018 Feb;
80:129-134.
PMID: 29414542
Objective: The objective was to assess the efficacy and safety of adjunctive brivaracetam (BRV) with concomitant use of lamotrigine (LTG) or topiramate (TPM) in patients with uncontrolled focal seizures. Methods:...
5.
Klein P, Diaz A, Gasalla T, Whitesides J
Clin Pharmacol
. 2018 Feb;
10:1-22.
PMID: 29403319
Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A)...
6.
Toledo M, Beale R, Evans J, Steeves S, Elmoufti S, Townsend R, et al.
Epilepsy Res
. 2017 Oct;
138:53-61.
PMID: 29073578
Antiepileptic drug (AED) retention rates are frequently reported in the literature and used to inform clinical decision-making, but methodological differences in the determination of retention rates make comparisons between trials...
7.
Asadi-Pooya A, Sperling M, Chung S, Klein P, Diaz A, Elmoufti S, et al.
Epilepsy Res
. 2017 May;
137:165-166.
PMID: 28501260
No abstract available.
8.
Asadi-Pooya A, Sperling M, Chung S, Klein P, Diaz A, Elmoufti S, et al.
Epilepsy Res
. 2017 Mar;
131:70-75.
PMID: 28279891
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This post-hoc...
9.
Klein P, Johnson M, Schiemann J, Whitesides J
Epilepsia
. 2016 Dec;
58(2):e21-e25.
PMID: 27988967
Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase...
10.
Moseley B, Sperling M, Asadi-Pooya A, Diaz A, Elmouft S, Schiemann J, et al.
Epilepsy Res
. 2016 Sep;
127:179-185.
PMID: 27608437
Purpose: Secondarily generalized tonic-clonic seizures (SGTCS) are among the most devastating types of seizures, contributing to increased morbidity and mortality. Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle 2A...